Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-040-0 | CAS number: 50-47-5
Endpoint summary
Administrative data
Description of key information
STOT SE 1 H370
In humans, desipramine induces central nervous system (CNS) and cardiovascular effects at therapeutic (0.5-2 mg/kg) and supratherapeutic doses. CNS effects are not limited to dizziness and vertigo, and include hallucinations due to the anticholinergic properties of the substance as well as seizures. Cardiovascular effects include tachycardia, QRS widening and hypotension.
[Antidepressants, tricyclic - Poisindex(R) Management]
STOT SE 3 H336
Dizziness and somnolence are common adverse effects (DrugPoints System).
Dizziness
a) Tricyclic antidepressants have been known to cause dizziness. Because desipramine is a tricyclic antidepressant, dizziness may occur with this drug (Prod Info NORPRAMIN(R) oral tablets, 2009).
Somnolence
a) Tricyclic antidepressants have been known to cause drowsiness. Because desipramine is a tricyclic antidepressant, drowsiness may occur with this drug (Prod Info NORPRAMIN(R) oral tablets, 2009).
[DRUGDEX® System: Klasco RK: DRUGDEX® System. Truven Health Analytics, Greenwood Village, Colorado.]
Even if the CNS mentioned adverse effects (i.e. dizziness, somnolence and CNS depression) were observed at therapeutic dose, and may have limited importance for industrial chemicals and their safety assessment, the substance is classified as STOT SE 3 H336, since it is not possible to establish if these type of effects are relevant at lower doses.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
